EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Engineering Murine Cross‐Reactivity Into an Affibody to Human Death Receptor 5

Tse-Han Kuo, Nagamani Vunnam, Jonathan N Sachs, Benjamin J Hackel

Biotechnology and Bioengineering · 2026

DOI: 10.1002/bit.70216 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology and Bioengineering, 2026. Verfasst von Tse-Han Kuo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Engineering and Materials Science, University of Minnesota - Twin Cities, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Receptors, TNF-Related Apoptosis-Inducing Ligand, Protein Engineering, Recombinant Fusion Proteins. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIBIB NIH HHS, NIGMS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interspecies cross‐reactive protein therapeutics that target conserved epitopes across species are critical for translational research. The present study showcases the engineering of an affibody molecule, originally discovered for binding to human death receptor 5 (hDR5) with 94 nM affinity, to simultaneously acquire cross‐reactivity to murine DR5 and enhance its binding affinity to human DR5. DR5 plays a pivotal role in metabolic dysfunction‐associated steatohepatitis (MASH) by mediating hepatocyte apoptosis and inflammation. Utilizing a rationally designed library guided by enrichment information and a helix‐walking mutagenesis strategy, combined with alternating binding selections between human and murine DR5, we evolved affibody variants exhibiting significantly improved binding to both receptors. Deep sequencing revealed amino acid preferences in the paratope, and the dominant variant, ABY DR5‐A , demonstrated over 1000‐fold and 16‐fold affinity improvements to murine and human DR5, respectively, with equilibrium dissociation constants of 15 and 5.8 nM. ABY DR5‐A exhibited nanomolar IC 50 values for antagonism of TRAIL‐induced DR5 signaling, measured via caspase 8 activation, in both murine and human cells, albeit with incomplete inhibition. This engineered affibody provides a promising candidate for therapeutic development targeting DR5‐mediated liver disease. Further functional characterization and pharmacokinetic optimization are required to advance these findings toward preclinical evaluation in murine MASH models and, ultimately, clinical applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, TNF-Related Apoptosis-Inducing LigandProtein EngineeringRecombinant Fusion ProteinsAnimalsHumansMiceCross ReactionsProtein Binding

Substanzen

Receptors, TNF-Related Apoptosis-Inducing LigandRecombinant Fusion ProteinsTNFRSF10B protein, human

Autor:innen und Institutionen

  • Department of Chemical Engineering and Materials Science, University of Minnesota - Twin Cities, Minneapolis, Minnesota, USA.
  • Department of Biomedical Engineering, University of Minnesota - Twin Cities, Minneapolis, Minnesota, USA.

Förderung

  • NIBIB NIH HHS
  • NIGMS NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Kuo, T. H., Vunnam, N., Sachs, J. N., & Hackel, B. J. (2026). Engineering Murine Cross‐Reactivity Into an Affibody to Human Death Receptor 5. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.70216

Vancouver

Kuo TH, Vunnam N, Sachs JN, Hackel BJ. Engineering Murine Cross‐Reactivity Into an Affibody to Human Death Receptor 5. Biotechnology and Bioengineering. 2026. doi:10.1002/bit.70216

BibTeX
@article{Kuo2026,
  author = {Kuo, Tse-Han and Vunnam, Nagamani and Sachs, Jonathan N and Hackel, Benjamin J},
  title = {Engineering Murine Cross‐Reactivity Into an Affibody to Human Death Receptor 5},
  journal = {Biotechnology and Bioengineering},
  year = {2026},
  doi = {10.1002/bit.70216}
}
Kostenlos starten →